Use of partial venovenous cardiopulmonary bypass in percutaneous hepatic perfusion for patients with diffuse, isolated liver metastases: A case series

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 28, Issue 3, 2014, Pages 647-651

  Fitzpatrick, Molly ^a   Richard Alexander, H ^a   Deshpande, Seema P ^a   Martz, Douglas G ^a   McCormick, Brian ^a   Grigore, Alina M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

liver metastases; percutaneous hepatic perfusion; venovenous cardiopulmonary bypass

Indexed keywords

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; FRESH FROZEN PLASMA; HEPARIN; HYPERTENSIVE FACTOR; MELPHALAN; PROTAMINE SULFATE; ALKYLATING AGENT;

ADULT; ARTERY PERFUSION; ARTICLE; BALLOON CATHETER; BLOOD PRESSURE REGULATION; CANCER CHEMOTHERAPY; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CRYOPRECIPITATE; DIFFUSE ISOLATED LIVER METASTASIS; EXPERIMENTAL THERAPY; FEMALE; HEMODYNAMICS; HEMOFILTRATION; HUMAN; HYPOTHERMIA; LIVER METASTASIS; LIVER PERFUSION; LIVER VEIN; MALE; METABOLIC ACIDOSIS; METASTATIC MELANOMA; MIDDLE AGED; PARTIAL VENOVENOUS CARDIOPULMONARY BYPASS; PERCUTANEOUS HEPATIC PERFUSION; PRIORITY JOURNAL; RESUSCITATION; SYSTEMIC CIRCULATION; VENOUS RETURN; BODY TEMPERATURE; CATHETERIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; LIVER CIRCULATION; LIVER NEOPLASMS; MELANOMA; MULTICENTER STUDY; PERFUSION; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SECONDARY;

ANTINEOPLASTIC AGENTS, ALKYLATING; BODY TEMPERATURE; CARDIOPULMONARY BYPASS; CATHETERIZATION; FEMALE; HEMOFILTRATION; HUMANS; LIVER CIRCULATION; LIVER NEOPLASMS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; PERFUSION;

EID: 84902248235     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2013.07.022     Document Type: Article

References (11)

1. T. Sato Locoregional management of hepatic metastasis from primary uveal melanoma Semin Oncol 37 2010 127 138
2. E.D. Feldman, and J.F. Pingpank et al. Regional treatment options for patients with ocular melanoma metastatic to the liver Ann Surg Oncol 11 2004 290 297
3. A. Jones, and H.R. Alexander Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies Surg Oncol Clin N Am 17 2008 857 876
4. H.R. Alexander, and C.C. Butler Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases Cancer J 16 2010 132 141
5. R.K. Ausman Development of a technique for isolated perfusion of the liver NY State J Med 61 1961 3393 3397
6. D. Han, G.M. Beasley, and D.S. Tyler et al. Minimally invasive intra-arterial regional therapy for metastatic melanoma: Isolated limb infusion and percutaneous hepatic perfusion Expert Opin Drug Metab Toxicol 7 2011 1383 1394
7. D. Christoforidis, O. Martinet, and F.J. Lejeune et al. Isolated liver perfusion for non-resectable liver tumours: A review Eur J Surg Oncol 28 2002 875 890
8. J.F. Pingpank, M.S. Hughes, and H.R. Alexander et al. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma June 2010 American Society of Clinical Oncology 2010 Annual Meeting Chicago, IL
9. H.R. Alexander et al. Percutaneous hepatic perfusion (PHP or Chemo SAT) with melphalan versus best alternative care (BAC) in patients (patients with hepatic metastases from melanoma: A post hoc analysis of PHP-randomized versus BAC-to-PHP crossover versus BAC only patients) June 2012 American Society of Clinical Oncology Annual Meeting Chicago, IL
10. T.S. Ravikumar, G. Pizzorno, and W. Bodden et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors J Clin Oncol 12 1994 2723 2736
11. N. Miao, J.F. Pingpank, and H.R. Alexander et al. Percutaneous hepatic perfusion in patients with metastatic liver cancer: Anesthetic, hemodynamic and metabolic considerations Ann Surg Oncol 15 2008 815 823